Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation With a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Composite end-point represented by the time in days from randomisation to the first occurrence of VTE
Symptomatic non-fatal DVTs. Symptomatic non-fatal PEs. Fatal PE. Incidental proximal DVT (popliteal vein or higher). Incidental proximal PE (segmental arteries or larger).
Agnes Y. Y. Lee, MD, MSc, FRCPC
Director of Thrombosis, Division of Hematology, University of British Columbia, Canada
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
IN 0901 INT